Break it Down: Orthocell books first sales revenue in US for Remplir
In this episode, host Tylah Tully takes a look at Orthocell (ASX:OCC), who have achieved first US revenue from Remplir, its flagship nerve repair product, after the company locked in FDA approval in April.
Tune in to hear all about it.
While Orthocell is a Stockhead advertiser, it did not sponsor this content.
Originally published as Break it Down: Orthocell books first sales revenue in US for Remplir
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
9 hours ago
- ABC News
NBA approves American record sale of Boston Celtics to private equity mogul Bill Chisholm
The NBA has unanimously approved the sale of the Boston Celtics to a group led by private equity mogul Bill Chisholm, a deal that values the franchise at $9.31 billion (US$6.1 billion). The league said the transaction is expected to close soon. When it does, Chisholm will take ownership of at least 51 per cent of the team, with full control coming by 2028 at a price that could bring the total value to $11.15 billion (US$7.3 billion). That's the largest price ever paid for an American professional sports team, though Los Angeles Dodgers owner Mark Walter has agreed to buy a controlling share of the Lakers in a deal that would place the value of the entire franchise at $15.27 billion (US$10 billion). It's not clear how much Walter would own; current owner Jeanie Buss is expected to retain at least 15 per cent of the team. The previous record for a US sports franchise was the US$6.05 billion paid for the NFL's Washington Commanders in 2023. The record price for an NBA team was the US$4 billion mortgage firm owner Mat Ishbia paid for the Phoenix Suns in 2023. A Massachusetts native and graduate of Dartmouth College and Penn's Wharton School of business, Chisholm is the managing partner of California-based Symphony Technology Group. The new ownership group also includes Boston businessmen Rob Hale, who is a current Celtics shareholder, and Bruce Beal Jr. Wyc Grousbeck led the ownership group that bought the team in 2002 for US$360 million and presided over NBA championships in 2008 and 2024. The franchise's 18 NBA titles is a record. Chisholm outbid at least two other groups, one led by previous Celtics minority partner Steve Pagliuca. Pagliuca has since announced plans to but the WNBA's Connecticut Sun for US$325 million and move them to Boston, but the women's league has baulked at the deal. AP
The Australian
10 hours ago
- The Australian
Argenica brain drug paces for FDA clearance
FDA provides clear path for Argenica to lift clinical hold on its ARG-007 stroke drug Further clarification on safety of dose in humans and three additional in vitro lab studies requested Company confident studies are straightforward and can be completed quickly Special Report: Argenica Therapeutics now has a clear path forward to clear the clinical hold currently in place on its investigational new drug application that will enable clinical trials for its lead drug ARG-007. In its full letter, the US Food and Drug Administration (FDA) requested additional information to provide assurance that proposed dosing for a US trial of ARG-007 in acute ischaemic stroke can be achieved safely in humans. The FDA has also requested that Argenica Therapeutics (ASX:AGN) conduct three additional in vitro cell culture studies with clinical research organisations to address identified gaps in data. AGN plans to use safety data from its Phase 2 acute ischaemic stroke trial, which will be available in September, as part of its response to the FDA's request for safety assurance. It adds that three additional studies are small ones that can be completed quickly and build on existing data it has already generated. 'We are pleased to have received the clarification from the FDA as to the additional information required to progress the IND application,' managing director Dr Liz Dallimore said. 'Importantly from a timing and cost perspective, the requested additional in vitro assays are standard assays which are straightforward and efficient to perform. 'Argenica will work with the FDA to ensure the proposed approach to providing the additional information is adequate to lift the clinical hold.' Preventing brain injury During acute neurological events such as stroke, traumatic brain injury (TBI), and hypoxic brain damage, around 1.9 million brain cells die for every minute that blood flow is halted. AGN's ARG-007 is a synthetic peptide designed to protect brain cells from dying in the critical minutes and hours by protecting brain tissue during and after these events. The company noted it was targeting acute ischaemic stroke as many patients that experienced it had a thrombectomy, where a radiologist inserts a catheter through the wrist or groin and guides it up into the brain to physically remove a clot. However, this process has the risk of reperfusion injury, which occurs when blood flow rapidly returns to previously oxygen-deprived brain tissue after a clot is removed and potentially causes additional damage. Dosing of patients in a double-blinded, randomised, placebo-controlled Phase 2 trial of ARG-007 in acute ischaemic stroke patients was completed in April. This involved 92 patients presenting to eight emergency departments around Australia with data-read out due in September with safety the main endpoint. The secondary endpoint for the trial will examine efficacy, with a brain scan taken 48 hours post administration of either the placebo or ARG-007. ARG-007 would be the first neuroprotective drug on the global market if approved, tapping into a large addressable global market for stroke and potentially other indications. The global stroke management market was valued at $36.1 billion in 2022, and is projected to reach $74 bn by 2032, driven by several factors including a growing ageing population. There are more than 45,000 strokes annually in Australia and 795,000 in the US – the world's largest healthcare markets. This article was developed in collaboration with Argenica Therapeutics, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
The Australian
10 hours ago
- The Australian
Cadillac set to name their first-ever F1 driver as they turn to unemployed six-time Grand Prix winner, 35, to lead team
Sergio Perez is edging closer to signing a deal with new F1 side Cadillac. The General Motors-backed team will make its debut on the grid in 2026 and are yet to announce their line up. Mexican driver Perez has not been in the paddock this season after he was axed by Red Bull last December. Fox Sports, available on Kayo Sports, is the only place to watch every practice, qualifying session and race in the 2025 FIA Formula One World Championship™ LIVE in 4K. New to Kayo? Join now and get your first month for just $1. But talks are ramping up with Cadillac and a deal could be announced in the coming weeks. Perez's Red Bull exit came after a run of woeful results where he failed to make a podium in his final 19 races. Sergio Perez had Daniel Ricciardo snapping at his heels while the Aussie was driving for Visa Cash App RB. (Photo by) In April, Perez made it clear he had spoken to a handful of teams and said: 'We are talking to a few parties out there. 'Once I know all my options, I will make a decision. What is very clear to me is that I'm only coming back if the project makes sense, and it's something I can enjoy.' Perez is a hot prospect given he is a six-time race winner and brings strong commercial appeal in Mexico. Mexican driver Sergio Perez struggled in his final years at Red Bull. (Photo by Andrej ISAKOVIC / AFP) The 35-year-old is also backed by Mexican billionaire Carlos Slim. Perez has reportedly held talks with Alpine with Franco Colapinto struggling to hit the ground running. Mercedes reserve driver Valtteri Bottas is said to be a favourite for the other Cadillac seat. Michael Schumacher's son Mick was also considered by the American team, having been out of F1 for three-years.
